News & Updates

In a prespecified analysis of the DELIVER* study, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the rate of total** heart failure (HF) events or cardiovascular (CV) deaths in HF patients with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF).

In the secondary analysis of the NAMSAL and ADVANCE trials, first-line treatment with dolutegravir (DTG) was associated with significantly higher risks of treatment-emergent hypertension in people living with HIV (PLWH), especially in combination with tenofovir alafenamide (TAF).

A strong association exists between polycystic ovarian syndrome (PCOS) and cardiovascular risk factors, but women with PCOS 40‒60 years of age are not at greater risk of cardiovascular morbidity and mortality, suggest the results of a study presented at the recent ESHRE 2023.

Treatment with either febuxostat or benzbromarone results in comparable outcomes among patients with stage G3 chronic kidney disease (CKD) with asymptomatic hyperuricaemia and hypertension, a study has shown.

Children and teens who watch a lot of television often grow to be adults with metabolic syndrome, obesity, or poor fitness, according to a study.

Worsening right ventricular (RV) function normally occurs in patients with heart failure and preserved left ventricular ejection fraction (HFpEF) and, along with its ratio to pulmonary pressure, is predictive of a higher risk of HF hospitalizations and cardiovascular death, reports a study.

Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) albiglutide results in fewer cardiovascular events, irrespective of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, among patients with type 2 diabetes (T2D) and cardiovascular disease, according to the post hoc analysis of Harmony Outcomes*.